Modality
Radioligand
MOA
CD3xCD20
Target
Nectin-4
Pathway
Checkpoint
ADPKD
Development Pipeline
Preclinical
Sep 2024
PreclinicalCurrent
NCT07366269
351 pts·ADPKD
2024-09→TBD·Active
NCT05064970
575 pts·ADPKD
2024-12→TBD·Completed
926 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Trial Timeline
Q4
Preclinical
Active
Preclinical
Complet…
ActiveCompleted|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07366269 | Preclinical | ADPKD | Active | 351 | DOR |
| NCT05064970 | Preclinical | ADPKD | Completed | 575 | PANSS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| LLY-1184 | Eli Lilly | NDA/BLA | C5 | |
| Zanuderotide | Novartis | Phase 1/2 | VEGF | |
| MRK-2473 | Merck & Co | Phase 1/2 | Nectin-4 | |
| NVO-1361 | Novo Nordisk | Phase 3 | CD38 | |
| Zorizanubrutinib | Novo Nordisk | Phase 1 | BTK | |
| DSN-1421 | Daiichi Sankyo | Phase 3 | Nectin-4 | |
| Pexamavacamten | Daiichi Sankyo | NDA/BLA | TIGIT | |
| ION-3857 | Ionis | Preclinical | Nectin-4 | |
| ITC-1028 | Intra-Cellular | Phase 2 | BCMA | |
| Semasacituzumab | Illumina | Phase 3 | Nectin-4 |